Phase 2CompletedAge-related condition
A Study of BAY3427080 (NT-814) in the Treatment of Moderate to Severe Post-menopausal Vasomotor Symptoms (SWITCH-1)
A Double-Blind, Randomised, Placebo Controlled, Adaptive Design Study of the Efficacy, Safety and Pharmacokinetics of NT-814 in Female Subjects With Moderate to Severe Vasomotor Symptoms Associated With the Menopause
- Sponsor
- Bayer (Industry)
- Enrollment
- 199 enrolled
- Conditions
- Menopause; Hot Flashes; Night Waking
- Interventions
- Elinzanetant (BAY3427080); Placebo
- Ages
- adults, older adults
- Registry
- NCT03596762, EUCTR2018-002763-26
Full record on ClinicalTrials.gov
From the registry
The purpose of this study is to determine the effectiveness of BAY3427080 (NT-814), taken once a day, in the treatment of troublesome post-menopausal symptoms.
Primary outcomes
- Mean Change From Baseline in Mean Daily Frequency of Moderate and Severe Hot Flushes From Baseline to Week 4
- Mean Change From Baseline in Mean Daily Frequency of Moderate and Severe Hot Flushes From Baseline to Week 12
- Mean Change From Baseline in Mean Severity of Moderate and Severe Hot Flushes From Baseline to Week 4
- Mean Change From Baseline in Mean Severity of Moderate and Severe Hot Flushes From Baseline to Week 12
History
Results first posted
Last registry update
Primary completion
Started
Registered
In the news
ConferenceBusiness Wire (opens Business Wire in a new tab)
Bayer presents post hoc sleep analysis of menopause drug elinzanetant’s two pivotal trials
The OASIS-1 and OASIS-2 subanalysis examined PROMIS questionnaire scores in women with moderate-to-severe vasomotor symptoms; Bayer presented the findings at the Menopause Society’s annual meeting.
